Disability Progression

For individuals with relapsing-remitting multiple sclerosis, fatigue levels were associated with disability rate, physical conditioning and activity level, according to research from Multiple Sclerosis and Related Disorders.

Longer-term treatment with ofatumumab led to lessening of disability progression and slowing of brain volume loss, according to Jeffrey A. Cohen, MD, in this Healio video.

An analysis of the Global Burden of Disease study showed that despite decreasing rates of CV death attributable to air pollution, the number of years living with disability increased from 1990 to 2019, especially among men.

AUSTIN, Texas – Children and adolescents diagnosed with anxiety, depression or both had greater headache-related disability compared with those without, according to a poster presented at the American Headache Society annual meeting.

AUSTIN, Texas — Migraine significantly affects work life and career in Canadian residents, with greater effect among those with more headache days per month, according to a poster at the American Headache Society annual meeting.

BOSTON — Worse cognitive processing speed at baseline was predictive of shorter time to disability progression in patients with MS, according to a poster at the American Academy of Neurology annual meeting.

Administration of Toll-receptor 4 antagonist ApTOLL within 6 hours of acute ischemic stroke, along with endovascular treatment, was linked to reduced mortality and disability at 90 days compared with placebo.

Greater eGFR variability predicts an increased risk of death, dementia, disability and CVD events among older and healthy adults, according to data published in Kidney Medicine.

The incidence of new disability and related outcomes at 6 months was similar between patients mechanically ventilated for COVID-19-related acute respiratory failure and other critically ill patients without COVID-19, researchers reported.

SEATTLE — Black patients with MS demonstrated a higher rate of disability throughout their disease course compared with white MS patients, according to a presenter at the 2022 American Academy of Neurology annual meeting.